Joe M. El Khoury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joe M. El Khoury has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Jillian Kodger
Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
9 shared publicationsMichael A. Vera
Departments of Laboratory Medicine, Yale School of Medicine, New Haven, CT, United States
7 shared publicationsDustin R. Bunch
Department of Laboratory Medicine, Yale University, New Haven, CT, United States
5 shared publicationsMichael A Vera
Department of Laboratory Medicine, Yale School of Medicine , New Haven, CT
5 shared publicationsChristopher D. Koch
Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
4 shared publicationsCristina Figueroa Villalba
Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
4 shared publications
Latest Publications
- 14 July 2026
- Published by Elsevier in Clinical Biochemistry
- Vol. 145, 111170
Reference interval evolution: what moving to the 99th percentile looks like for a comprehensive metabolic panel in an outpatient setting
- 14 July 2026
- Published by Elsevier in Clinical Biochemistry
- Vol. 145, 111170
Reference interval evolution: what moving to the 99th percentile looks like for a comprehensive metabolic panel in an outpatient setting
- Open Access
- 29 June 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (6) , 1442-1451
Rapid Diagnosis of Intrahepatic Cholestasis of Pregnancy (ICP): Validation of an Automated Enzymatic Total Bile Acid Assay and Assessment of Ursodeoxycholic Acid Impact on Bile Acid Profiles in an ICP Cohort
Background: Intrahepatic cholestasis of pregnancy (ICP) requires timely diagnosis to guide management, including initiation of ursodeoxycholic acid (UDCA) and delivery planning. LC-MS/MS provides fractionated bile acid profiles but has a turnaround time (TAT) of approximately 1 week, delaying treatment. Enzymatic total bile acid (TBA) assays offer faster results but measure all bile acids collectively, which some have reported can be impacted by UDCA treatment. Methods: We validated the Diazyme enzymatic TBA assay on a Roche Cobas analyzer, assessing analytical measurement range, reference interval, precision, and accuracy vs LC-MS/MS. The comparison cohort included samples from 100 pregnant patients (median age 31 years; gestational age 34 weeks) presenting with pruritus and suspected of ICP. A secondary analysis examined UDCA and tauroursodeoxycholic acid in a UDCA-detectable subset. TAT was evaluated retrospectively in 971 specimens. Results: We verified the assay’s analytical measurement range of 1 to 180 µmol/L and reference interval of <10 µmol/L. Precision was <10%, and method comparison revealed minimal bias, with 98% clinical concordance. In the UDCA subset (n = 19), UDCA and tauroursodeoxycholic acid represented minor fractions of total TBA. Operationally, the enzymatic assay provided rapid results, with a median TAT of 5.6 h from collection (range 0.6–36.8) and 0.5 h from receipt (range 0.2–22.3); delays were mainly due to transport. Conclusions: The Diazyme enzymatic TBA assay on Roche Cobas demonstrates robust performance and rapid turnaround, supporting timely ICP diagnosis and management. LC-MS/MS remains useful for fractionated profiling but is limited by longer TAT.
- 29 June 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (6) , 1442-1451
Open AccessRapid Diagnosis of Intrahepatic Cholestasis of Pregnancy (ICP): Validation of an Automated Enzymatic Total Bile Acid Assay and Assessment of Ursodeoxycholic Acid Impact on Bile Acid Profiles in an ICP Cohort
Background: Intrahepatic cholestasis of pregnancy (ICP) requires timely diagnosis to guide management, including initiation of ursodeoxycholic acid (UDCA) and delivery planning. LC-MS/MS provides fractionated bile acid profiles but has a turnaround time (TAT) of approximately 1 week, delaying treatment. Enzymatic total bile acid (TBA) assays offer faster results but measure all bile acids collectively, which some have reported can be impacted by UDCA treatment. Methods: We validated the Diazyme enzymatic TBA assay on a Roche Cobas analyzer, assessing analytical measurement range, reference interval, precision, and accuracy vs LC-MS/MS. The comparison cohort included samples from 100 pregnant patients (median age 31 years; gestational age 34 weeks) presenting with pruritus and suspected of ICP. A secondary analysis examined UDCA and tauroursodeoxycholic acid in a UDCA-detectable subset. TAT was evaluated retrospectively in 971 specimens. Results: We verified the assay’s analytical measurement range of 1 to 180 µmol/L and reference interval of <10 µmol/L. Precision was <10%, and method comparison revealed minimal bias, with 98% clinical concordance. In the UDCA subset (n = 19), UDCA and tauroursodeoxycholic acid represented minor fractions of total TBA. Operationally, the enzymatic assay provided rapid results, with a median TAT of 5.6 h from collection (range 0.6–36.8) and 0.5 h from receipt (range 0.2–22.3); delays were mainly due to transport. Conclusions: The Diazyme enzymatic TBA assay on Roche Cobas demonstrates robust performance and rapid turnaround, supporting timely ICP diagnosis and management. LC-MS/MS remains useful for fractionated profiling but is limited by longer TAT.
- 24 June 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (9) , 1003-1004
TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations
- 24 June 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (9) , 1003-1004
TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations
- 10 June 2026
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 57 (4)
Establishing multianalyte thresholds for automated detection of EDTA contamination.
Bias in analytes due to EDTA contamination is easy to miss and represents a common and clinically relevant preanalytical error. We designed a study to determine the in vitro effects of rising rates of EDTA contamination in blood samples and to evaluate how these findings could inform the development of multianalyte thresholds for detecting such errors automatically. We incrementally spiked blood samples with increasing volumes of EDTA‑contaminated specimen and measured the resulting changes in alkaline phosphatase, calcium, magnesium, potassium, and iron levels. Using these observations, we developed a series of multianalyte thresholds and evaluated their performance against 1 year of retrospective clinical data (n = 2407). Our experiments demonstrated that increasing rates of EDTA contamination produced changes in several analytes. Accordingly, we applied multianalyte thresholds using potassium and calcium to retrospective samples. Across all samples, smaller magnitudes of analyte deviation resulted in higher detection rates of subtle EDTA contamination but poorer specificity. We selected a rule of a potassium level of 6.5 mmol/L or higher and a calcium level below 6.5 mg/dL (1.63 mmol/L), which identified 14 samples with a contamination rate of 42.8%. Multianalyte thresholds show promise as an effective approach for automatically identifying clinically significant EDTA contamination in clinical specimens.
- 10 June 2026
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 57 (4)
Establishing multianalyte thresholds for automated detection of EDTA contamination.
Bias in analytes due to EDTA contamination is easy to miss and represents a common and clinically relevant preanalytical error. We designed a study to determine the in vitro effects of rising rates of EDTA contamination in blood samples and to evaluate how these findings could inform the development of multianalyte thresholds for detecting such errors automatically. We incrementally spiked blood samples with increasing volumes of EDTA‑contaminated specimen and measured the resulting changes in alkaline phosphatase, calcium, magnesium, potassium, and iron levels. Using these observations, we developed a series of multianalyte thresholds and evaluated their performance against 1 year of retrospective clinical data (n = 2407). Our experiments demonstrated that increasing rates of EDTA contamination produced changes in several analytes. Accordingly, we applied multianalyte thresholds using potassium and calcium to retrospective samples. Across all samples, smaller magnitudes of analyte deviation resulted in higher detection rates of subtle EDTA contamination but poorer specificity. We selected a rule of a potassium level of 6.5 mmol/L or higher and a calcium level below 6.5 mg/dL (1.63 mmol/L), which identified 14 samples with a contamination rate of 42.8%. Multianalyte thresholds show promise as an effective approach for automatically identifying clinically significant EDTA contamination in clinical specimens.
- 20 May 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (8) , 819-820
ADOPT Automated Phlebotomy: Exceptional Performance. Unproven Generalizability across Skin Tones
- 20 May 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (8) , 819-820
ADOPT Automated Phlebotomy: Exceptional Performance. Unproven Generalizability across Skin Tones
- Open Access
- 7 March 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (3) , 429-432
Acute Kidney Injury Alert! KDIGO vs AACC-AKI Criteria
- 7 March 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (3) , 429-432
Open AccessAcute Kidney Injury Alert! KDIGO vs AACC-AKI Criteria
- 19 January 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 584, 120846
Validating CALIPER pediatric reference intervals in a U.S. population using retrospective outpatient data and RefineR
- 19 January 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 584, 120846
Validating CALIPER pediatric reference intervals in a U.S. population using retrospective outpatient data and RefineR
- 28 December 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (1)
Reply to correspondence: haptoglobin in pregnancy
- 28 December 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (1)
Reply to correspondence: haptoglobin in pregnancy
- 26 November 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 581, 120741
Liquid chromatography-mass spectrometry quantitation and prevalence of medetomidine and xylazine in New Haven, Connecticut
- 26 November 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 581, 120741
Liquid chromatography-mass spectrometry quantitation and prevalence of medetomidine and xylazine in New Haven, Connecticut
- 20 November 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (4) , 813-820
Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse
Recreational nitrous oxide (N 2 O) use has emerged as a growing public health concern, with increasing reports of neurological, psychiatric, and thrombotic complications. This position paper from the EFLM Committee on Biological Markers of Nitrous Oxide Abuse highlights the urgent need for clinical and laboratory awareness, alongside coordinated action from healthcare systems and the scientific community. Short-term recommendations focus on early clinical recognition, prompt biological testing, and structured patient management. Key clinical symptoms include unexplained sensory disturbances, gait instability, bladder and bowel complaints, sexual dysfunction, mood disorders, and thromboembolic events in young individuals. Plasma homocysteine (HCY) and plasma methylmalonic acid (MMA) are central to the diagnostic approach, with HCY serving as a sensitive marker of recent exposure and MMA indicating clinical severity. Vitamin B12 and folate measurements are also essential, though B12 levels may be falsely reassuring (often in the low-normal range). Given the rapid normalization of biomarkers, testing should be performed on admission, and vitamin B12 supplementation should begin without delay, with caution regarding biomarker kinetics and possible self-supplementation by patients. In addition, this paper outlines long-term goals, including the harmonization of biomarker assays, creation of international patient registries, and development of interdisciplinary expert networks. Notably, the international network PROTOSIDE ( www.protoside.com ) plays a key role in facilitating case discussion, expert collaboration, and dissemination of best practices in the management of N 2 O-related complications. A continuous bibliographic watch and support for translational research are necessary to improve biomarker discovery and understanding of the underlying mechanisms of toxicity. By combining immediate clinical action with long-term scientific and policy development, this document lays the foundation for an international strategy to address the silent but expanding epidemic of nitrous oxide misuse.
- 20 November 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (4) , 813-820
Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse
Recreational nitrous oxide (N 2 O) use has emerged as a growing public health concern, with increasing reports of neurological, psychiatric, and thrombotic complications. This position paper from the EFLM Committee on Biological Markers of Nitrous Oxide Abuse highlights the urgent need for clinical and laboratory awareness, alongside coordinated action from healthcare systems and the scientific community. Short-term recommendations focus on early clinical recognition, prompt biological testing, and structured patient management. Key clinical symptoms include unexplained sensory disturbances, gait instability, bladder and bowel complaints, sexual dysfunction, mood disorders, and thromboembolic events in young individuals. Plasma homocysteine (HCY) and plasma methylmalonic acid (MMA) are central to the diagnostic approach, with HCY serving as a sensitive marker of recent exposure and MMA indicating clinical severity. Vitamin B12 and folate measurements are also essential, though B12 levels may be falsely reassuring (often in the low-normal range). Given the rapid normalization of biomarkers, testing should be performed on admission, and vitamin B12 supplementation should begin without delay, with caution regarding biomarker kinetics and possible self-supplementation by patients. In addition, this paper outlines long-term goals, including the harmonization of biomarker assays, creation of international patient registries, and development of interdisciplinary expert networks. Notably, the international network PROTOSIDE ( www.protoside.com ) plays a key role in facilitating case discussion, expert collaboration, and dissemination of best practices in the management of N 2 O-related complications. A continuous bibliographic watch and support for translational research are necessary to improve biomarker discovery and understanding of the underlying mechanisms of toxicity. By combining immediate clinical action with long-term scientific and policy development, this document lays the foundation for an international strategy to address the silent but expanding epidemic of nitrous oxide misuse.